No Data
CCORF Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $12
AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Otsuka Holdings Co (OtherOTSKF) and AngioDynamics (ANGO)
AngioDynamics' NanoKnife System Gains CPT Codes for Prostate and Liver Treatments
AngioDynamics Announces American Medical Association's CPT Editorial Panel Grants Category I CPT for Irreversible Electroporation (IRE) in Prostate and Liver
CEO, President & Director of AngioDynamics James Clemmer Buys 4.4% More Shares